Via CBC: Federal gov’t announces $24.5M in cannabis research grants “For too long many people have based their medical use of cannabis on anecdotal evidence, and frankly that’s not good enough.” The money will fund 26 projects, three of which will be undertaken in Calgary, where researchers will study: Cannabinoid
IRVINE, CA, May 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has entered into a new Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc. to investigate the potential use of a proprietary extract from the Justicia
From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology. In this randomized, double-blind study (ClinicalTrials.gov identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis or
Creso Pharma just signed a 3-year deal with TerrAscend Canada to supply the company with 100 KG of cannabis every month. As reported in the Australian publication SmallCaps: The company today announced the signing of a three-year agreement to supply a minimum of 100kg of cannabis flower per month to
In another historic first for advancing research into the uses of cannabis for pharmaceutical purposes, the University of Washington (UW) has entered into a deal with Canadian-based Pascal Biosciences. Negotiated by CoMotion, UW’s incubation group, the partnership involves UW licensing a cannabinoid-based compound, ST-403 (ST) for use in various pharma products.
The research is planned to take place at the newly licensed Lumir Lab, which is located on the Hebrew University campus. According to the article, there are over 180 million women worldwide who suffer from the condition. According to Gynica, the female human reproductive organs contain the most receptors for cannabinoids,
According to a recent announcement made by Revive Therapeutics, the company has been granted an FDA Orphan Drug Designation for the use of cannabidiol (“CBD”) in preventing ischemia and reperfusion injury (“IRI”) — both of which can result from solid organ transplantation. Under the Orphan Drug Act of 1983, the FDA
In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures the